• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Obese patients with NASH have increased hepatic expression of SARS-CoV-2 critical entry points.

作者信息

Fondevila Marcos F, Mercado-Gómez Maria, Rodríguez Amaia, Gonzalez-Rellan Maria J, Iruzubieta Paula, Valentí Víctor, Escalada Javier, Schwaninger Markus, Prevot Vincent, Dieguez Carlos, Crespo Javier, Frühbeck Gema, Martinez-Chantar Maria L, Nogueiras Ruben

机构信息

Department of Physiology, CIMUS, University of Santiago de Compostela-Instituto de Investigación Sanitaria, Santiago de Compostela, Spain; CIBER Fisiopatologia de la Obesidad y Nutrición (CIBERobn), Spain.

Liver Disease Laboratory, Center for Cooperative Research in Biosciences (CIC bioGUNE, Basque Research and Technology Alliance (BRTA), Bizkaia Technology Park, Building 801A, 48160 Derio, and CIBER de Enfermedades Hepaticas y Digestivas (CIBERehd), Spain.

出版信息

J Hepatol. 2021 Feb;74(2):469-471. doi: 10.1016/j.jhep.2020.09.027. Epub 2020 Oct 20.

DOI:10.1016/j.jhep.2020.09.027
PMID:33096086
原文链接:
https://pmc.ncbi.nlm.nih.gov/articles/PMC7574841/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c4aa/7574841/c14c102dc143/gr1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c4aa/7574841/c14c102dc143/gr1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c4aa/7574841/c14c102dc143/gr1_lrg.jpg

相似文献

1
Obese patients with NASH have increased hepatic expression of SARS-CoV-2 critical entry points.患有非酒精性脂肪性肝炎（NASH）的肥胖患者肝脏中严重急性呼吸综合征冠状病毒2（SARS-CoV-2）关键进入点的表达增加。
J Hepatol. 2021 Feb;74(2):469-471. doi: 10.1016/j.jhep.2020.09.027. Epub 2020 Oct 20.
2
Commentary: Obesity: The "Achilles heel" for COVID-19?评论：肥胖：新冠病毒的“阿喀琉斯之踵”？
Metabolism. 2020 Jul;108:154251. doi: 10.1016/j.metabol.2020.154251. Epub 2020 Apr 27.
3
No evidence for an increased liver uptake of SARS-CoV-2 in metabolic-associated fatty liver disease.在代谢相关脂肪性肝病中，没有证据表明严重急性呼吸综合征冠状病毒2（SARS-CoV-2）的肝脏摄取增加。
J Hepatol. 2020 Sep;73(3):717-718. doi: 10.1016/j.jhep.2020.04.035. Epub 2020 Apr 30.
4
Assessing the consequences of environmental exposures on the expression of the human receptor and proteases involved in SARS-CoV-2 cell-entry.评估环境暴露对 SARS-CoV-2 细胞进入所涉及的人类受体和蛋白酶表达的影响。
Environ Res. 2021 Apr;195:110317. doi: 10.1016/j.envres.2020.110317. Epub 2020 Oct 15.
5
Polyunsaturated ω-3 fatty acids inhibit ACE2-controlled SARS-CoV-2 binding and cellular entry.多不饱和 ω-3 脂肪酸抑制 ACE2 控制的 SARS-CoV-2 结合和细胞进入。
Sci Rep. 2021 Mar 4;11(1):5207. doi: 10.1038/s41598-021-84850-1.
6
Not only ACE2-the quest for additional host cell mediators of SARS-CoV-2 infection: Neuropilin-1 (NRP1) as a novel SARS-CoV-2 host cell entry mediator implicated in COVID-19.不仅仅是ACE2——对严重急性呼吸综合征冠状病毒2（SARS-CoV-2）感染的其他宿主细胞介质的探索：神经纤毛蛋白-1（NRP1）作为一种与2019冠状病毒病（COVID-19）相关的新型SARS-CoV-2宿主细胞进入介质
Signal Transduct Target Ther. 2021 Jan 18;6(1):21. doi: 10.1038/s41392-020-00460-9.
7
Closing the portal to SARS-CoV-2 cellular entry: May open newer avenues….关闭SARS-CoV-2细胞进入的门户：可能会开辟新的途径……
Med Hypotheses. 2021 Jan;146:110464. doi: 10.1016/j.mehy.2020.110464. Epub 2020 Dec 22.
8
Simultaneous Inhibition of SARS-CoV-2 Entry Pathways by Cyclosporine.环孢素同时抑制 SARS-CoV-2 的进入途径。
ACS Chem Neurosci. 2021 Mar 3;12(5):930-944. doi: 10.1021/acschemneuro.1c00019. Epub 2021 Feb 19.
9
Epithelial and Endothelial Expressions of ACE2: SARS-CoV-2 Entry Routes.上皮细胞和内皮细胞 ACE2 的表达：SARS-CoV-2 的进入途径。
J Pharm Pharm Sci. 2021;24:84-93. doi: 10.18433/jpps31455.
10
SARS-CoV-2 entry in host cells-multiple targets for treatment and prevention.SARS-CoV-2 进入宿主细胞的途径——治疗和预防的多个靶点。
Biochimie. 2020 Aug;175:93-98. doi: 10.1016/j.biochi.2020.05.012. Epub 2020 May 29.

引用本文的文献

1
Post-COVID-19 Pandemic Sequelae in Liver Diseases.新冠疫情后肝脏疾病的后遗症
Life (Basel). 2025 Mar 4;15(3):403. doi: 10.3390/life15030403.
2
Hepatic angiotensin-converting enzyme 2 expression in metabolic dysfunction-associated steatotic liver disease and in patients with fatal COVID-19.代谢相关脂肪性肝病及致死性 COVID-19 患者肝组织血管紧张素转换酶 2 的表达。
World J Gastroenterol. 2024 Aug 21;30(31):3705-3716. doi: 10.3748/wjg.v30.i31.3705.
3
Histopathological impact of SARS-CoV-2 on the liver: Cellular damage and long-term complications.

本文引用的文献

1
Metabolic-associated fatty liver disease is associated with severity of COVID-19.代谢相关脂肪性肝病与 COVID-19 的严重程度相关。
Liver Int. 2020 Sep;40(9):2160-2163. doi: 10.1111/liv.14575. Epub 2020 Jul 5.
2
Association of Blood Glucose Control and Outcomes in Patients with COVID-19 and Pre-existing Type 2 Diabetes.COVID-19 合并 2 型糖尿病患者的血糖控制与结局的相关性。
Cell Metab. 2020 Jun 2;31(6):1068-1077.e3. doi: 10.1016/j.cmet.2020.04.021. Epub 2020 May 1.
3
No evidence for an increased liver uptake of SARS-CoV-2 in metabolic-associated fatty liver disease.
SARS-CoV-2 对肝脏的组织病理学影响：细胞损伤和长期并发症。
World J Gastroenterol. 2024 Jun 14;30(22):2866-2880. doi: 10.3748/wjg.v30.i22.2866.
4
Molecular mechanisms underlying SARS-CoV-2 hepatotropism and liver damage.新型冠状病毒2型嗜肝性和肝损伤的分子机制
World J Hepatol. 2024 Jan 27;16(1):1-11. doi: 10.4254/wjh.v16.i1.1.
5
SARS-CoV-2 receptor ACE2 is upregulated by fatty acids in human MASH.严重急性呼吸综合征冠状病毒2（SARS-CoV-2）受体血管紧张素转换酶2（ACE2）在人原代脂肪干细胞中被脂肪酸上调。
JHEP Rep. 2023 Oct 13;6(1):100936. doi: 10.1016/j.jhepr.2023.100936. eCollection 2024 Jan.
6
The causal association between polycystic ovary syndrome and susceptibility and severity of COVID-19: a bidirectional Mendelian randomization study using genetic data.多囊卵巢综合征与 COVID-19 易感性和严重程度之间的因果关系：使用遗传数据进行的双向孟德尔随机化研究。
Front Endocrinol (Lausanne). 2023 Sep 8;14:1229900. doi: 10.3389/fendo.2023.1229900. eCollection 2023.
7
Unraveling the Molecular and Cellular Pathogenesis of COVID-19-Associated Liver Injury.解析 COVID-19 相关肝损伤的分子和细胞发病机制。
Viruses. 2023 May 30;15(6):1287. doi: 10.3390/v15061287.
8
The Intersection of COVID-19 and Metabolic-Associated Fatty Liver Disease: An Overview of the Current Evidence.新型冠状病毒肺炎与代谢相关脂肪性肝病的关系：当前证据概述。
Viruses. 2023 Apr 27;15(5):1072. doi: 10.3390/v15051072.
9
COVID-19 and MAFLD/NAFLD: An updated review.2019冠状病毒病与代谢功能障碍相关脂肪性肝病/非酒精性脂肪性肝病：最新综述
Front Med (Lausanne). 2023 Mar 24;10:1126491. doi: 10.3389/fmed.2023.1126491. eCollection 2023.
10
COVID-19 and the liver: Are footprints still there?COVID-19 与肝脏：是否仍有踪迹可循？
World J Gastroenterol. 2023 Jan 28;29(4):656-669. doi: 10.3748/wjg.v29.i4.656.
在代谢相关脂肪性肝病中，没有证据表明严重急性呼吸综合征冠状病毒2（SARS-CoV-2）的肝脏摄取增加。
J Hepatol. 2020 Sep;73(3):717-718. doi: 10.1016/j.jhep.2020.04.035. Epub 2020 Apr 30.
4
Younger patients with MAFLD are at increased risk of severe COVID-19 illness: A multicenter preliminary analysis.患有MAFLD的年轻患者患重症COVID-19疾病的风险增加：一项多中心初步分析。
J Hepatol. 2020 Sep;73(3):719-721. doi: 10.1016/j.jhep.2020.04.027. Epub 2020 Apr 26.
5
Non-alcoholic fatty liver diseases in patients with COVID-19: A retrospective study.新型冠状病毒肺炎患者的非酒精性脂肪性肝病：一项回顾性研究。
J Hepatol. 2020 Aug;73(2):451-453. doi: 10.1016/j.jhep.2020.03.044. Epub 2020 Apr 8.
6
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.严重急性呼吸综合征冠状病毒 2 型（SARS-CoV-2）进入细胞依赖于 ACE2 和 TMPRSS2，可被一种临床验证的蛋白酶抑制剂所阻断。
Cell. 2020 Apr 16;181(2):271-280.e8. doi: 10.1016/j.cell.2020.02.052. Epub 2020 Mar 5.
7
NAFLD: a multisystem disease.非酒精性脂肪性肝病：一种多系统疾病。
J Hepatol. 2015 Apr;62(1 Suppl):S47-64. doi: 10.1016/j.jhep.2014.12.012.
8
DNA methylation analysis in nonalcoholic fatty liver disease suggests distinct disease-specific and remodeling signatures after bariatric surgery.非酒精性脂肪性肝病的 DNA 甲基化分析表明，减肥手术后存在独特的疾病特异性和重塑特征。
Cell Metab. 2013 Aug 6;18(2):296-302. doi: 10.1016/j.cmet.2013.07.004.
9
The role of estrogens in control of energy balance and glucose homeostasis.雌激素在能量平衡和葡萄糖稳态控制中的作用。
Endocr Rev. 2013 Jun;34(3):309-38. doi: 10.1210/er.2012-1055. Epub 2013 Mar 4.